Drugs / recombinant human IL-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07011004 Background | May 2025 → May 2028 expected | acute myeloid leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05218408 Background | Sep → Oct 2021 | giant cell glioblastoma | Celularity Incorporated | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human IL-2 | “Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.” NCT07011004 ↗1“subcutaneous recombinant human IL-2 following lymphodepleting chemotherapy.” NCT05218408 ↗ |
| Known as | rh-IL2 | “Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.” NCT07011004 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interleukin-2” NCT05218408 ↗ |
| Route | Subcutaneous | “subcutaneous recombinant human IL-2” NCT05218408 ↗ |